Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Condition(s):Solid Tumor; ARID1A Gene MutationLast Updated:April 18, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Solid Tumor; ARID1A Gene MutationLast Updated:April 18, 2023Recruiting
Condition(s):Recurrent Endometrial Carcinoma; Recurrent Ovarian Carcinoma; ARID1A Gene MutationLast Updated:February 15, 2024Recruiting
Condition(s):Solid Tumors; ER+ Breast Cancer; Triple Negative Breast Cancer, TNBC; ARID1A Gene Mutation; Small Cell Lung Cancer, SCLCLast Updated:January 6, 2023Recruiting
Condition(s):Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Locally Advanced Urethral Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Bladder Urothelial Carcinoma; Recurrent Renal Pelvis Urothelial Carcinoma; Recurrent Ureter Urothelial Carcinoma; Recurrent Urethral Urothelial Carcinoma; Recurrent Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8; Stage IIIB Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Stage IVA Bladder Cancer AJCC v8; Stage IVB Bladder Cancer AJCC v8; Unresectable Bladder Urothelial Carcinoma; Unresectable Renal Pelvis Urothelial Carcinoma; Unresectable Ureter Urothelial Carcinoma; Unresectable Urethral Urothelial Carcinoma; Unresectable Urothelial CarcinomaLast Updated:February 8, 2024Recruiting
Condition(s):Advanced Solid Tumor; Ovarian Cancer; Ovarian Clear Cell Carcinoma; Ovarian Clear Cell Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Endometrioid Tumor; ARID1A Gene MutationLast Updated:February 28, 2024Recruiting
Condition(s):NSCLC Stage IV; ARID1A; PD-1Last Updated:February 25, 2020Unknown status
Condition(s):Metastatic AdenocarcinomaLast Updated:October 28, 2020Withdrawn
Condition(s):Metastatic Malignant Solid Neoplasm; Unresectable Solid NeoplasmLast Updated:February 9, 2024Recruiting
Condition(s):Gynecologic Neoplasms; Epithelial Ovarian CancerLast Updated:October 5, 2022Terminated
Condition(s):Metastatic MelanomaLast Updated:December 6, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.